Openbookopenbook
Equity
DNA
+0.0 · +0.00%
USD · NYSE

Ginkgo Bioworks Holdings(DNA) Stock Analysis | Healthcare

USD --+0.00%
Reward40Moderate
Risk67Medium-High
75%Data
Thin -220% profit margin · Revenue down 49% YoY
Earnings Deterioration
Market Cap:498.32M
ⓘ
Reward Rating
40
Moderate
Reward Assessment
75% data coverage
Bottom 10% of stocksView factors
ⓘ
Risk Rating
67
Medium-High
Risk Assessment
8 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on DNA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for DNA, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $7.00.

What is Ginkgo Bioworks Holdings?

, together with its subsidiaries, develops a platform for cell engineering in the United States.

DNA · Verdict

Moderate reward · elevated risk

DNA has limited near-term tailwinds — cash flow and volatility weigh on the model output.

Based on 88% data coverage

DNA · Verdict

What’s working & what to watch

Watchouts 4

  • Cash flow16/100

    -105% free-cash-flow margin

  • Volatility20/100

    Weak vs peers

  • Growth30/100

    Rev -29.1% CAGR · earnings -47.0%

  • Profitability32/100

    -184% net margin · -60% ROE

Model-based scoring. For information only — not financial advice.

What is Ginkgo Bioworks Holdings?

, together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 498.32M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

SOLTFMicro Cap / 497M market cap
Sosei Group Corporation
Compare
CCCCMicro Cap / 494M market cap
C4 Therapeutics Inc
Compare
OABIMicro Cap / 491M market cap
OmniAb Inc.
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap498.32M
P/E RatioN/A
Dividend YieldN/A
Beta1.789
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
11542,981 shares
$3.5M
0
6-9months
21,708 shares
$15k
0
9-12months
26,921 shares
$102k
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.